This article was originally published in The Gray Sheet
Executive SummaryFirm's branched DNA Quantiplex HIV-1 RNA 3.0 viral load test will be released this summer for research use. The device offers improved sensitivity over the current 2.0 version and quantifies "as little as 50 copies/mL and a broad dynamic range (50 to 500,000 copies/mL) that eliminates the need for reflex testing," Chiron says
You may also be interested in...
Keytruda is set to remain dominant despite knockback, though Tecentriq could claim prized NSCLC adjuvant approval first
Vertex is hoping for EU approval in Q4 of its cystic fibrosis triple combination therapy, Trikafta. It wants the same licence in the EU as it has in the US, where the product has already become a best seller for the company.